Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Down 97.8% in April

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the target of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totaling 16 shares, a decrease of 97.8% from the April 15th total of 719 shares. Based on an average trading volume of 3,446 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Ascentage Pharma Group International Trading Down 1.0%

AAPG traded down $0.21 during trading on Wednesday, hitting $20.96. The company’s stock had a trading volume of 1,902 shares, compared to its average volume of 3,242. Ascentage Pharma Group International has a twelve month low of $19.11 and a twelve month high of $48.45. The stock’s fifty day moving average price is $23.95 and its 200-day moving average price is $26.94. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The firm had revenue of $24.72 million for the quarter. As a group, sell-side analysts predict that Ascentage Pharma Group International will post -1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on AAPG shares. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target for the company. BTIG Research reiterated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 target price for the company. Finally, China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $46.67.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several institutional investors have recently made changes to their positions in AAPG. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $96,000. ABC Arbitrage SA acquired a new stake in Ascentage Pharma Group International in the third quarter valued at approximately $204,000. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International in the third quarter valued at approximately $383,000. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International during the second quarter valued at approximately $391,000. Finally, XY Capital Ltd raised its position in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.